drugset / Trial / NCT03580694
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.
Timeline
- Start
- 2018-06-27
- Primary completion
- 2019-12-04
- Completion
- 2019-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | REGN4659 | Monoclonal antibody | — | Intravenous |